Sarcoma / 2013 / Article / Tab 1 / Clinical Study
Low-Grade Fibromyxoid Sarcoma: Incidence, Treatment Strategy of Metastases, and Clinical Significance of the FUS Gene Table 1 Clinical data, followup, and FUS break-apart in 14 patients with low-grade fibromyxoid sarcoma, diagnosed at the Sarcoma Centre of Aarhus University Hospital in the period of 1979 to 2010.
Case Age/sex Size Location Depth Treatment Margin Relapse time/location Relapse treatment Followup FUS 1 8/M 8 Pelvic Subfascial Surgery Marginal 8.0/Local, intra-abdominal Surgery, chemo- + radiotherapy 24.3 Neg. 2 38/F 4 Hand Subfascial Surgery + radiotherapy Marginal 17.5/Local Surgery 21.7 Neg. 3 54/F 3 Thigh Subcutaneous Surgery Wide 6.0 Neg. 4 37/F 6 Thigh Subfascial Surgery Wide 5.0 Pos. 5 14/M 5 Brachium Subfascial Surgery Marginal 4.8 Neg. 6 37/F 26 Gluteal Subfascial Surgery Marginal 4.1/Local None 9.0 Pos. 7 53/F 2 Neck/head Subfascial Surgery Marginal 7.7 Neg. 8 24/F 25 Abdominal wall Subfascial Surgery Wide 4.6 Neg. 9 30/F 3 Abdominal wall Subfascial Surgery Marginal 1.9/Local Surgery 2.5 Neg. 10 35/M 4 Neck/head Subfascial Surgery Wide 5.2 Neg. 11 64/M 9 Gluteal Subfascial Surgery Marginal 5.0 Neg. 12 14/M 3 Brachium Subfascial Surgery Marginal 4.0 Pos. 13 18/F 9 Gluteal Subfascial Chemotherapy 0/Lung, liver Chemotherapy 3.2 Neg. 14 63/F 3 Gluteal Subfascial Surgery Marginal −0.3/Lung, brachium, and thigh Surgery 2.8 Neg.